Title : CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.

Pub. Date : 2013 Nov 26

PMID : 24169346






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. ARQ 197 cytochrome P450 family 2 subfamily C member 19 Homo sapiens
2 Polymorphisms of CYP2C19, the key metabolic enzyme for tivantinib, should be addressed to translate the previous Western study to Asian population, because higher incidence of poor metabolisers (PMs) is reported in Asian population. ARQ 197 cytochrome P450 family 2 subfamily C member 19 Homo sapiens
3 CONCLUSION: Two doses of tivantinib in combination with erlotinib were recommended based on CYP2C19 genotype: 360 mg BID for EMs and 240 mg BID for PMs. ARQ 197 cytochrome P450 family 2 subfamily C member 19 Homo sapiens